Diseases & Conditions
Grants & Contracts
News & Events
February 27, 2023
Some responses to the mRNA COVID-19 vaccines reported as severe allergic reactions were likely a recently described, non-allergic condition called immunization stress-related response (ISRR), according to a study by investigators. The symptoms of ISRR can closely mimic those of a severe allergic reaction known as anaphylaxis, a potentially life-threatening, systemic allergic reaction in which the immune system releases a dangerous flood of chemicals.
January 24, 2023
NIAID scientists have found an association between widely used chemicals called diisocyanates and atopic dermatitis, a chronic inflammatory skin disease commonly known as eczema.
January 10, 2023
Two recently published studies explain why some people respond better to vaccines than others and could guide the development of new strategies to enhance the antibody response to vaccination.
January 05, 2023
Research by NIAID grantees strongly suggests that immune responses to a newly discovered species of gut bacteria may cause some cases of a common autoimmune disease called rheumatoid arthritis. The findings were recently published in Science Translational Medicine.
October 19, 2022
Women are disproportionately affected by HIV, with young women in sub-Saharan Africa three times as likely to be infected than young men in the same age group. In 2015, the World Health Organization (WHO) recommended that tenofovir-based pre-exposure prophylaxis (PrEP) be offered to high-risk individuals for prevention. As a result, oral PrEP has been introduced in more than 70 countries, including sub-Saharan Africa.
October 17, 2022
The National Institute of Allergy and Infectious Diseases, a part of NIH, stands with the scientific community in recognizing October as Eczema Awareness Month and acknowledging the need for continued research into possible cures and therapeutics.
September 15, 2022
The first Food and Drug Administration approval of a treatment for eosinophilic esophagitis, announced in May 2022, marked a vital achievement not only for people with the disease, but also for scientists including a NIAID grantee whose research helped lay a foundation for this milestone.
August 17, 2022
An investigational typhoid vaccine containing a component developed with NIAID funding may overcome some of the shortcomings of available typhoid vaccines, according to a paper published in the journal Vaccine in June.
July 14, 2021
A study funded by the National Institute of Allergy and Infectious Diseases contributes to the evidence for a new guideline on how to induce remission and treat relapse of a rare, severe autoimmune disease called ANCA-associated vasculitis.
June 17, 2021
Nearly a third of infants who are hospitalized with a severe form of a common childhood lung infection called bronchiolitis develop asthma a few years later. However, clinicians have been unable to predict which infants with severe bronchiolitis are at high risk for developing asthma and to understand why. Now, a NIAID-funded study published in the journal Nature Communications has taken a step toward accomplishing this.
February 09, 2021
NIAID-funded research has expanded the toolbox of medical countermeasures available in case a catastrophic event exposes people to high doses of radiation.
May 01, 2020
A new NIAID-supported study has begun to track the immune responses of people hospitalized with COVID-19 in 10 research sites across the United States.
February 20, 2020
Information about NIAID’s commitment to addressing rare diseases through gene therapy and beyond.